Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer

INTRODUCTION: Concurrent chemoradiotherapy with conventional fractionation has been acknowledged as one of the standard treatments for locally advanced non-small cell lung cancer (NSCLC). The radiotherapy dose of 60 Gy is far from enough for local tumour control. Due to this fact, hypofractionated r...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yue-E, Xue, Xiao-Ying, Zhang, Rui, Chen, Xue-Ji, Ding, Yu-Xia, Liu, Chao-Xing, Qin, Yue-Liang, Li, Wei-Qian, Ren, Xiao-Cang, Lin, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590348/
https://www.ncbi.nlm.nih.gov/pubmed/33099491
http://dx.doi.org/10.1136/bmjopen-2019-036295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590348/
https://www.ncbi.nlm.nih.gov/pubmed/33099491
http://dx.doi.org/10.1136/bmjopen-2019-036295

Ejemplares similares